Want to see SE:ONCOZ full AI Analyst Report?
Top Page
OncoZenge AB
(ONCOZ)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr3.50
▼(-36.48% Downside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by weak financial performance—large losses, high cash burn, and negative equity create significant funding/solvency risk despite improving revenue. Technicals further weigh on the score with a clear downtrend (below major moving averages and negative MACD), while valuation is only mildly supportive because losses (negative P/E) reduce interpretability and there is no dividend yield.
Positive Factors
Strong Revenue Growth
The more than doubling of trailing revenue indicates improving commercialization traction for the company’s product, albeit from a small base. If sustained, this growth can strengthen operating leverage, expand market reach, and provide a better foundation for funding development over the next several quarters.
Negative Factors
Persistent Large Net Losses
The scale of recurring losses relative to approximately 5.8m of revenue shows that the current cost base remains far above the company’s commercial earnings capacity. Continued losses could require prolonged external funding and may delay the point at which growth translates into sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The more than doubling of trailing revenue indicates improving commercialization traction for the company’s product, albeit from a small base. If sustained, this growth can strengthen operating leverage, expand market reach, and provide a better foundation for funding development over the next several quarters.
Read all positive factors
OncoZenge AB (ONCOZ) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr88.18M
Dividend YieldN/A
Average Volume (3M)55.89K
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth115.26%
EPS Growth-230.43%
CountrySE
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.92
Shares Outstanding25,936,514
10 Day Avg. Volume122,580
30 Day Avg. Volume55,891
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-139.70
Price to Sales (P/S)30.78
P/FCF Ratio-6.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.83
Revenue Forecast (FY)kr5.00M
OncoZenge AB Business Overview & Revenue Model
Company Description
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clin...
How the Company Makes Money
OncoZenge’s business model is centered on monetizing its drug candidate/product BupiZenge™ through commercialization and partnering. Expected revenue streams typically include: (1) product sales in markets where the company commercializes directly...
OncoZenge AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.84M | 2.66M | 1.00K | 3.00K | 0.00 | 0.00 |
| Gross Profit | 3.96M | -4.84M | 1.00K | 3.00K | 0.00 | 0.00 |
| EBITDA | -25.44M | -15.87M | -8.69M | 7.27M | 2.77M | -4.89M |
| Net Income | -26.18M | -15.94M | -8.69M | -15.90M | -46.65M | -3.89M |
Balance Sheet | ||||||
| Total Assets | 11.73M | 15.34M | 11.43M | 20.34M | 36.89M | 85.23M |
| Cash, Cash Equivalents and Short-Term Investments | 749.00K | 3.71M | 3.86M | 12.63M | 29.14M | 51.22M |
| Total Debt | 7.50M | 7.50M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 17.03M | 15.92M | 1.48M | 1.70M | 2.92M | 4.90M |
| Stockholders Equity | -5.30M | -587.00K | 9.95M | 18.64M | 33.97M | 80.32M |
Cash Flow | ||||||
| Free Cash Flow | -10.73M | -13.06M | -8.76M | -17.08M | -22.08M | -10.12M |
| Operating Cash Flow | -23.79M | -13.06M | -8.76M | -17.08M | -22.08M | -4.77M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 570.00K | 0.00 | -5.36M |
| Financing Cash Flow | 22.98M | 12.91M | 0.00 | 0.00 | 0.00 | 51.34M |
OncoZenge AB Technical Analysis
Negative
5.51
Price Trends
5.11
Negative
5.39
Negative
5.15
Negative
Market Momentum
-0.48
Positive
27.58
Positive
8.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCOZ, the sentiment is Negative. The current price of 5.51 is above the 20-day moving average (MA) of 4.42, above the 50-day MA of 5.11, and above the 200-day MA of 5.15, indicating a bearish trend. The MACD of -0.48 indicates Positive momentum. The RSI at 27.58 is Positive, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ONCOZ.
OncoZenge AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr473.10M | 2.35 | 63.09% | ― | ― | ― | |
53 Neutral | kr634.23M | -2.09 | ― | ― | 87.23% | 35.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr234.60M | -3.73 | -54.41% | ― | ― | 32.79% | |
48 Neutral | kr189.53M | -7.70 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr466.24M | -3.88 | -18.05% | ― | ― | 15.97% | |
44 Neutral | kr88.18M | -1.80 | -2775.09% | ― | 115.26% | -230.43% |
* Healthcare Sector Average
SE:ONCOZ
OncoZenge AB
3.46
-1.80
-34.17%
SE:ONCO
Oncopeptides AB
1.63
-3.11
-65.58%
SE:ISOFOL
Isofol Medical AB
0.76
-0.04
-4.64%
SE:ELIC
Elicera Therapeutics AB
2.73
-3.05
-52.83%
SE:IMMU
Immunicum AB
6.95
-0.89
-11.35%
SE:CANTA
Cantargia AB
1.60
-1.12
-41.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.